Ardelyx presents real-world tenapanor effectiveness analysis in dialysis patients at ASN Kidney Week 2026

By Public Technologies
  • Ardelyx flagged new research on hyperphosphatemia management scheduled for presentation at ASN Kidney Week 2026 in Denver.
  • Data include real-world analyses of tenapanor use alongside phosphate binders, focusing on how patients fare in routine clinical practice.
  • Separate work examines patient-reported challenges in managing hyperphosphatemia, highlighting treatment burden and adherence obstacles.
  • Another analysis links long-term hyperphosphatemia exposure in dialysis patients with higher risks of illness and death.
  • An exhibitor session will outline XPHOZAH’s mechanism, safety, and practical add-on use for patients not reaching guideline phosphorus targets on binders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050801PRIMZONEFULLFEED9839302) on October 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk